Neuphoria Therapeutics Faces Delisting Notice

TL;DR

Neuphoria Therapeutics got a notice about failing to meet listing rules - big trouble ahead?

AI Summary

Neuphoria Therapeutics Inc. filed an 8-K on December 18, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of listing. The company was formerly known as Bionomics Limited/FI until September 20, 2002.

Why It Matters

This filing indicates potential issues with Neuphoria Therapeutics' continued listing on an exchange, which could significantly impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards is a severe event that can lead to the cessation of trading on a major exchange.

Key Players & Entities

• Neuphoria Therapeutics Inc. (company) — Registrant
• BIONOMICS LIMITED/FI (company) — Former company name
• December 18, 2025 (date) — Date of report
• 001-41157 (other) — Commission File Number
• 99-3845449 (other) — I.R.S. Employer Identification No.

FAQ

Key Financial Figures

• $0.00001 — nge on which registered Common Stock, $0.00001 par value per share NEUP The Nasdaq

Filing Documents

• ea0270248-8k_neuphoria.htm (8-K) — 26KB
• 0001213900-25-123289.txt ( ) — 186KB
• neup-20251218.xsd (EX-101.SCH) — 3KB
• neup-20251218_lab.xml (EX-101.LAB) — 33KB
• neup-20251218_pre.xml (EX-101.PRE) — 22KB
• ea0270248-8k_neuphoria_htm.xml (XML) — 3KB

01. Notice

Item 3.01. Notice of Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on July 18, 2025, Neuphoria Therapeutics Inc. (the "Company") received a deficiency notification letter (the " Notice ") from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (" Nasdaq "). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5620(a) (the " Listing Rule ") as a result of the Company's failure to hold a qualified annual meeting of stockholders within twelve months of the end of the Company's fiscal year ended June 30, 2024. Consistent with past practice, whereby the Company has held a shareholder meeting in each of the past number of years on or about November or December of each such year, the Company successfully held its 2025 annual general shareholder meeting on December 12, 2025 in satisfaction of the compliance item provided in the Notice. As a result, on December 18, 2025 the Company received a further written Notice from Nasdaq's Staff stating that it has determined that the Company has regained compliance with the Listing Rule and this matter is now closed.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K includes forward-looking forward-looking statements and factors that may cause such differences include, without limitation, the ability of the Company to maintain the listing of its securities on Nasdaq and the risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. 1

SIGNATUREs

SIGNATUREs Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NEUPHORIA THERAPEUTICS INC. By: /s/ Spyridon Papapetropoulos Spyridon Papapetropoulos Chief Executive Officer Date: December 18, 2025 2

View Full Filing

View this 8-K filing on SEC EDGAR